<DOC>
	<DOCNO>NCT02081690</DOCNO>
	<brief_summary>Prospective , multi-center , open-label , single-arm , Phase 3b psychometric validation study . Primary objective : To evaluate psychometric characteristic reliability construct validity French , Italian Spanish version PAH-SYMPACT™ . To evaluate ability French , Italian Spanish version PAH SYMPACT™ detect change . Secondary objective : To assess safety macitentan patient pulmonary arterial hypertension ( PAH ) . Exploratory objective : To explore effect macitentan PAH symptom impact ( measure PAH-SYMPACT™ ) patient PAH France , Italy Spain .</brief_summary>
	<brief_title>A Pulmonary Arterial Hypertension Study With Macitentan Validate PAH-SYMPACT™ France , Italy Spain</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Macitentan</mesh_term>
	<criteria>1 . Signed informed consent prior initiation studymandated procedure . 2 . Patients symptomatic PAH WHO Functional Class ( FC ) II III . 3 . Patients PAH belong one follow subgroup Dana Point Clinical Classification Group 1 : 1 . Idiopathic , , 2 . Heritable , , 3 . Drug toxin induce , , 4 . Associated one following : i. Connective tissue disease , ii . Congenital heart disease simple systemictopulmonary shunt least 1 year surgical repair , iii . HIV infection . 4 . Documented hemodynamic diagnosis PAH right heart catheterization perform time prior Screening showing : 1 . Resting mean pulmonary arterial pressure ( mPAP ) ≥ 25 mmHg , 2 . Resting pulmonary vascular resitance ( PVR ) &gt; 240 dyn.s.cm5 , 3 . Pulmonary capillary wede pressure ( PCWP ) leave ventricular end diastolic pressure ( LVEDP ) ≤ 15 mmHg . 5 . 6minute walk distance ( 6MWD ) ≥ 150 Screening . 6 . Able fluently speak read local language . 7 . Men woman age 1880 ; woman childbearing potential ( define ) must : 1 . Have negative serum pregnancy test Screening negative urine pregnancy test Baseline agree perform monthly serum pregnancy test , , 2 . Agree use two reliable method contraception parallel , Screening Visit 1 1 month study drug discontinuation ( see detail ) . A female consider childbearing potential unless meet least one follow criterion : Previous bilateral salpingo and/or oophorectomy , hysterectomy . Premature ovarian failure confirm specialist . Prepubescence , XY genotype , Turner syndrome , uterine agenesis . Postmenopausal , define 12 consecutive month menses without alternative medical cause . Of two contraceptive method must use , one must Group 1 , one must Group 2 , define follow : Group 1 : Oral , implantable , transdermal injectable hormonal contraceptive , intrauterine device , female sterilization ( tubal ligation non surgical sterilization , e.g. , permanent contraception Essure procedure ) , partner 's sterilization ( vasectomy ) . If hormonal contraceptive choose group , must take least 1 month prior enrollment . Alternatively , Essure procedure choose contraceptive method , hysterosalpingogram must perform confirm correct location microinserts tubal occlusion ( per manufacturer 's recommendation ) . Group 2 : Female male condom , diaphragm cervical cap , combination spermicide . Sexual abstinence , rhythm method , contraception partner alone consider acceptable method contraception study . 1 . Known moderatetosevere obstructive lung disease ( i.e. , force expiratory volume one second [ FEV1 ] &lt; 80 % predict , FEV1 / force vital capacity [ FVC ] &lt; 70 % ) know significant chronic lung disease diagnose chest imaging ( e.g. , interstitial lung disease , emphysema ) . 2 . Known moderatetosevere restrictive lung disease ( i.e. , total lung capacity [ TLC ] &lt; 60 % predict value ) . 3 . Hemoglobin &lt; 100g/L Screening . 4 . Serum aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) &gt; 3 X upper limit normal range ( ULN ) Screening . 5 . Patients undergoing dialysis . 6 . Systolic blood pressure ( SBP ) &lt; 90 mmHg Screening . 7 . Body weight &lt; 40 kg Screening . 8 . Known concomitant lifethreatening disease life expectancy &lt; 12 month . 9 . Treatment ERAs within 3 month prior Visit 2 , schedule receive compound , macitentan , trial . 10 . Treatment intravenous subcutaneous prostacyclin prostacyclin analog within 3 month prior Visit 2 , schedule receive compound trial . 11 . Treatment soluble guanylate cyclase stimulator ( riociguat ) within 3 month prior Visit 2 , schedule receive riociguat trial . 12 . Patients change dose discontinued phosphodiesterase type5 inhibitor ( PDE5i ) , inhaled prostacyclin analogue , calcium channel blocker within 3 month prior Visit 2 . 13 . Initiation diuretic within 1 week prior Baseline period . 14 . Patients oral diuretic dose stable least 1 week prior Baseline period . 15 . Treatment cytochrome P4500 ( CYP ) 3A inducer within 4 week prior Visit 2 . 16 . Recently start ( &lt; 8 week prior Visit 2 ) plan cardiopulmonary rehabilitation program base exercise . 17 . Females lactate pregnant ( positive Screening Baseline pregnancy test ) plan become pregnant study . 18 . Known hypersensitivity macitentan excipients drug class . 19 . Treatment another investigational drug within 3 month prior Visit 2 . 20 . Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>PAH-SYMPACT</keyword>
	<keyword>psychometric instrument</keyword>
</DOC>